Goldenwell Biotech, Inc. (GWLL)

OTCMKTS · Delayed Price · Currency is USD
1.050
-0.057 (-5.15%)
At close: Feb 2, 2026
425.00%
Market Cap 103.95M
Revenue (ttm) 62.34K
Net Income (ttm) -75.12K
Shares Out 99.00M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 500
Average Volume 913
Open 1.050
Previous Close 1.107
Day's Range 1.050 - 1.050
52-Week Range 0.200 - 10.000
Beta 6.23
RSI 43.86
Earnings Date May 8, 2026

About Goldenwell Biotech

Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio. [Read more]

Industry Packaged Foods
Founded 2019
Country United States
Stock Exchange OTCMKTS
Ticker Symbol GWLL
Full Company Profile

Financial Performance

In 2024, Goldenwell Biotech's revenue was $139, a decrease of -92.43% compared to the previous year's $1,836. Losses were -$131,498, 12.0% more than in 2023.

Financial Statements

News

There is no news available yet.